MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in MiNK Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −11 vs. Q1 2022
- Shares held
- 357.4K
- −425.1K (−54.3%) vs. Q1 2022
- Total value
- $504.0K
- −$1.26M (−71.4%) vs. Q1 2022
- New holders
- 1
- 2 more added
- Sold out
- 12
- 8 more reduced
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.39M |
| Q1 2026 | 23 | $1.34M |
| Q4 2025 | 25 | $1.71M |
| Q3 2025 | 18 | $1.28M |
| Q2 2025 | 19 | $460.8K |
| Q1 2025 | 17 | $544.2K |
| Q4 2024 | 23 | $564.9K |
| Q3 2024 | 26 | $632.3K |
| Q2 2024 | 31 | $847.8K |
| Q1 2024 | 34 | $848.1K |
| Q4 2023 | 36 | $1.05M |
| Q3 2023 | 36 | $800.0K |
| Q2 2023 | 45 | $3.10M |
| Q1 2023 | 12 | $1.15M |
| Q4 2022 | 16 | $1.70M |
| Q3 2022 | 11 | $1.00M |
| Q2 2022 | 13 | $504.0K |
| Q1 2022 | 25 | $1.76M |
| Q4 2021 | 21 | $5.96M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding MiNK Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Artal Group S.A. | 289,588 | $408.0K | 0.02% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 35,500 | $50.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 23,175 | $32.0K | 0.00% | −10,729−31.6% | Reduced |
| BlackRock Inc. | 6,639 | $10.0K | 0.00% | −11,005−62.4% | Reduced |
| Tower Research Capital LLC (TRC) | 1,104 | $2.00K | 0.00% | −1,165−51.3% | Reduced |
| FMR LLC | 374 | $1.00K | 0.00% | +217+138.2% | Added |
| Morgan Stanley | 463 | $1.00K | 0.00% | +373+414.4% | Added |
| UBS Group AG | 258 | $0 | 0.00% | −5,103−95.2% | Reduced |
| Bank of America Corp | 1 | $0 | 0.00% | −1,994−99.9% | Reduced |
| JPMorgan Chase & Co | 247 | $0 | 0.00% | −694−73.8% | Reduced |
| Wells Fargo & Company | 22 | $0 | 0.00% | −423−95.1% | Reduced |
| Citigroup Inc | 21 | $0 | 0.00% | −58−73.4% | Reduced |
| Credit Suisse AG | 1 | $0 | 0.00% | +1 | New |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −331,002−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −25,760−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −16,776−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −10,348−100.0% | Sold out |
| New York State Common Retirement Fund | 0 | $0 | 0.00% | −8,000−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −996−100.0% | Sold out |
| California State Teachers Retirement System | 0 | $0 | 0.00% | −709−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −327−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −295−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −124−100.0% | Sold out |
| Ameritas Investment Partners, Inc. | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |